Vicore Pharma Holding AB (publ) (VICO.ST)
SEK 6.95
(6.6%)
SEK 6.95
(6.6%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -317.46 Million SEK | -10.92% |
| 2022 | -286.2 Million SEK | 1.65% |
| 2021 | -293.12 Million SEK | -100.44% |
| 2020 | -143.77 Million SEK | -56.94% |
| 2019 | -92.51 Million SEK | -269.96% |
| 2018 | -38.24 Million SEK | -95.57% |
| 2017 | -23.81 Million SEK | -92.47% |
| 2016 | -6.64 Million SEK | -46.42% |
| 2015 | -4.53 Million SEK | -132.81% |
| 2014 | -4.92 Million SEK | 1128.87% |
| 2013 | -1.46 Million SEK | -77008.43% |
| 2012 | -1743.00 SEK | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 27.01 Million SEK | 124.05% |
| 2024 Q2 | -61.89 Million SEK | -305.74% |
| 2023 Q4 | -69.42 Million SEK | -9.06% |
| 2023 Q1 | -66.02 Million SEK | -5.12% |
| 2023 Q2 | -69.29 Million SEK | -4.95% |
| 2023 FY | - SEK | -10.92% |
| 2023 Q3 | -63.65 Million SEK | 8.13% |
| 2022 Q1 | -90.95 Million SEK | -8.9% |
| 2022 Q2 | -64.34 Million SEK | 29.26% |
| 2022 FY | - SEK | 1.65% |
| 2022 Q3 | -68.57 Million SEK | -6.57% |
| 2022 Q4 | -62.81 Million SEK | 8.4% |
| 2021 Q1 | -47.39 Million SEK | 18.81% |
| 2021 Q4 | -83.51 Million SEK | 13.42% |
| 2021 Q3 | -96.46 Million SEK | -41.36% |
| 2021 Q2 | -68.24 Million SEK | -43.99% |
| 2021 FY | - SEK | -100.44% |
| 2020 FY | - SEK | -56.94% |
| 2020 Q1 | -28.49 Million SEK | 3.53% |
| 2020 Q3 | -34.23 Million SEK | -42.01% |
| 2020 Q4 | -58.37 Million SEK | -70.52% |
| 2020 Q2 | -24.1 Million SEK | 15.39% |
| 2019 FY | - SEK | -269.96% |
| 2019 Q4 | -29.53 Million SEK | -31.15% |
| 2019 Q3 | -22.51 Million SEK | 9.2% |
| 2019 Q2 | -24.79 Million SEK | -54.99% |
| 2019 Q1 | -16 Million SEK | 34.29% |
| 2018 Q4 | -24.35 Million SEK | -344.36% |
| 2018 Q3 | -5.48 Million SEK | -198.95% |
| 2018 Q1 | 4.62 Million SEK | 173.65% |
| 2018 FY | - SEK | -95.57% |
| 2018 Q2 | 5.53 Million SEK | 19.71% |
| 2017 FY | - SEK | -92.47% |
| 2017 Q4 | -6.28 Million SEK | -272.98% |
| 2017 Q3 | -1.68 Million SEK | 26.72% |
| 2017 Q2 | -2.29 Million SEK | -25.37% |
| 2017 Q1 | -1.83 Million SEK | -1.78% |
| 2016 Q1 | -1.91 Million SEK | -35.57% |
| 2016 FY | - SEK | -46.42% |
| 2016 Q3 | -1.58 Million SEK | -18.28% |
| 2016 Q2 | -1.34 Million SEK | 30.1% |
| 2016 Q4 | -1.8 Million SEK | -13.63% |
| 2015 Q1 | -1.08 Million SEK | 30.49% |
| 2015 FY | - SEK | -132.81% |
| 2015 Q2 | -1.09 Million SEK | -0.74% |
| 2015 Q4 | -1.41 Million SEK | -49.0% |
| 2015 Q3 | -949 Thousand SEK | 13.02% |
| 2014 Q4 | -1.55 Million SEK | -107.73% |
| 2014 Q3 | -750 Thousand SEK | 42.68% |
| 2014 FY | - SEK | 1128.87% |
| 2014 Q2 | -1.3 Million SEK | 0.0% |
| 2014 Q1 | -1.3 Million SEK | -136.19% |
| 2013 Q1 | -559.00 SEK | 29.55% |
| 2013 Q3 | -402.5 Thousand SEK | 28.0% |
| 2013 Q4 | -554 Thousand SEK | -37.64% |
| 2013 FY | - SEK | -77008.43% |
| 2013 Q2 | -559 Thousand SEK | -99900.0% |
| 2012 Q3 | -347.75 SEK | 0.0% |
| 2012 Q4 | -793.50 SEK | -128.18% |
| 2012 FY | - SEK | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Calliditas Therapeutics AB (publ) | -367.8 Million SEK | 13.686% |
| Camurus AB (publ) | 562.54 Million SEK | 156.434% |
| Mendus AB (publ) | -97.84 Million SEK | -224.455% |
| Lipum AB (publ) | -37.11 Million SEK | -755.265% |
| NextCell Pharma AB | -40.98 Million SEK | -674.588% |
| Simris Alg AB (publ) | -22.36 Million SEK | -1319.604% |
| Elicera Therapeutics AB (publ) | -17.08 Million SEK | -1758.209% |
| Active Biotech AB (publ) | -43.88 Million SEK | -623.371% |
| Amniotics AB (publ) | -27.14 Million SEK | -1069.605% |
| Asarina Pharma AB (publ) | -14.21 Million SEK | -2133.003% |
| BioArctic AB (publ) | 275.38 Million SEK | 215.28% |
| Cantargia AB (publ) | -284.31 Million SEK | -11.66% |
| Scandinavian ChemoTech AB (publ) | -19.57 Million SEK | -1521.462% |
| CombiGene AB (publ) | -35.33 Million SEK | -798.419% |
| Diamyd Medical AB (publ) | -140.85 Million SEK | -125.391% |
| Genovis AB (publ.) | 64.57 Million SEK | 591.647% |
| Guard Therapeutics International AB (publ) | -114.9 Million SEK | -176.281% |
| Isofol Medical AB (publ) | -37.02 Million SEK | -757.46% |
| Intervacc AB (publ) | -68.98 Million SEK | -360.229% |
| Kancera AB (publ) | -61.88 Million SEK | -412.96% |
| Karolinska Development AB (publ) | -26.78 Million SEK | -1085.327% |
| LIDDS AB (publ) | -39.67 Million SEK | -700.267% |
| Lipigon Pharmaceuticals AB (publ) | -12.1 Million SEK | -2522.819% |
| Magle Chemoswed Holding AB (publ) | 31.4 Million SEK | 1110.909% |
| OncoZenge AB (publ) | 7.26 Million SEK | 4469.199% |
| Saniona AB (publ) | -69.69 Million SEK | -355.508% |
| Xbrane Biopharma AB (publ) | -282.03 Million SEK | -12.563% |
| Xintela AB (publ) | -53.47 Million SEK | -493.716% |
| Xspray Pharma AB (publ) | -169.81 Million SEK | -86.948% |
| Ziccum AB (publ) | -20.34 Million SEK | -1460.643% |
| Modus Therapeutics Holding AB (publ) | 2000.00 SEK | 15873400.0% |
| Alligator Bioscience AB (publ) | -237.61 Million SEK | -33.606% |
| Sprint Bioscience AB (publ) | -2.08 Million SEK | -15162.788% |
| QuiaPEG Pharmaceuticals Holding AB (publ) | -13.43 Million SEK | -2263.681% |
| Corline Biomedical AB | -1.69 Million SEK | -18673.862% |
| IRLAB Therapeutics AB (publ) | -173.32 Million SEK | -83.163% |
| Bio-Works Technologies AB (publ) | -54.8 Million SEK | -479.254% |
| Aptahem AB (publ) | -10 Million SEK | -3071.733% |
| Infant Bacterial Therapeutics AB (publ) | 11.54 Million SEK | 2848.861% |
| Fluicell AB (publ) | -25.91 Million SEK | -1125.075% |
| Biovica International AB (publ) | -119.5 Million SEK | -165.649% |
| Spago Nanomedical AB (publ) | -42.22 Million SEK | -651.862% |
| AcouSort AB (publ) | -16.7 Million SEK | -1800.653% |
| Abliva AB (publ) | -93.6 Million SEK | -239.144% |
| Egetis Therapeutics AB (publ) | -319.1 Million SEK | 0.512% |
| 2cureX AB (publ) | -35.13 Million SEK | -803.535% |
| I-Tech AB | 30.34 Million SEK | 1146.189% |
| Hansa Biopharma AB (publ) | -714.55 Million SEK | 55.571% |
| Cyxone AB (publ) | -20.41 Million SEK | -1455.139% |
| ExpreS2ion Biotech Holding AB (publ) | -102.45 Million SEK | -209.865% |
| Biosergen AB | 228 Thousand SEK | 139339.474% |
| Nanologica AB (publ) | -62.11 Million SEK | -411.061% |
| SynAct Pharma AB | -222.7 Million SEK | -42.553% |
| Annexin Pharmaceuticals AB (publ) | -43.86 Million SEK | -623.8% |
| BioInvent International AB (publ) | -312.7 Million SEK | -1.522% |
| Stayble Therapeutics AB (publ) | 309.41 Thousand SEK | 102702.67% |
| Alzinova AB (publ) | 41.99 Thousand SEK | 755989.426% |
| Oncopeptides AB (publ) | -231.62 Million SEK | -37.062% |
| Pila Pharma AB (publ) | -8.81 Million SEK | -3502.46% |
| Ascelia Pharma AB (publ) | -108.55 Million SEK | -192.439% |
| Diagonal Bio AB (publ) | -11.46 Million SEK | -2668.036% |